RMC No. 99-2021 clarifies VAT exemption for COVID-19 medicines and medical devices. Only items on the FDA consolidated list are exempt, effective June 17, 2021, with specific input VAT rules.
Businesses handling COVID-19 related medicines and medical devices must now follow the clarified VAT exemption rules issued by the Bureau of Internal Revenue. Only items listed in the FDA-submitted consolidated list, published in RMC No. 81-2021, are exempt from VAT, effective from June 17, 2021. Misapplication or reliance on previous lists may result in incorrect VAT reporting.
What Changed
RMC No. 99-2021 updates prior circulars and revenue regulations to provide clarity on the VAT exemption for medicines and medical devices related to COVID-19. This circular confirms that the consolidated list issued by the FDA and circularized under RMC No. 81-2021 is now the controlling reference. Previous lists under RMC Nos. 4-2019, 62-2020, and 101-2020 are superseded.
Who Is Affected
The circular primarily affects manufacturers, distributors, wholesalers, and retailers of medicines and medical devices prescribed for COVID-19. Taxpayers involved in the importation or sale of these products must ensure they follow the updated exemption guidelines, specifically observing the listed dosage strength, form, and route of administration.
Key Compliance Requirements and Deadlines
The VAT exemption takes effect on the publication date of the FDA’s consolidated list, which is June 17, 2021. Only products enumerated in this list with the exact dosage specifications are exempt. For input VAT paid on on-hand inventories before the effective date, taxpayers may carry over the amount to succeeding taxable quarters or include it as part of cost under Section 110 of the Tax Code.
Refunds for erroneously paid VAT on local purchases and importations prior to the effective date are not allowed except in cases where VAT registration status changes. Input VAT already claimed in monthly or quarterly VAT returns cannot be claimed again under Section 204(C).
Penalties for Non-Compliance
Improper application of VAT exemption, such as relying on outdated lists or claiming input VAT twice, may lead to misreporting and potential administrative penalties. All internal revenue officers and employees are instructed to ensure wide publicity and compliance.
Practical Steps for Businesses
Businesses should immediately review their inventories and sales records against the FDA’s consolidated list of VAT-exempt products. Update accounting systems to reflect only the approved items as VAT-exempt. Consult with tax advisors to ensure proper treatment of unutilized input VAT and avoid duplicate claims. Maintain documentation supporting product inclusion in the consolidated list.
For comprehensive guidance and compliance assistance with RMC No. 99-2021, businesses can rely on the expertise of Ablola, Saribong & Gueco. Our team provides detailed advisory services to ensure accurate VAT application and proper reporting. Visit MakatiLawFirm.com for more information and personalized consultation.